Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura

por Bergstrand, Martin, Hansson, Emma, Delaey, Bernard, Callewaert, Filip, De Passos Sousa, Rui, Sargentini‐Maier, Maria Laura
Publicado 2021

Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in Mice

por Terryn, Sanne, Francart, Aurélie, Lamoral, Sophie, Hultberg, Anna, Rommelaere, Heidi, Wittelsberger, Angela, Callewaert, Filip, Stohr, Thomas, Meerschaert, Kris, Ottevaere, Ingrid, Stortelers, Catelijne, Vanlandschoot, Peter, Kalai, Michael, Van Gucht, Steven
Publicado 2014

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study

por Knoebl, Paul, Cataland, Spero, Peyvandi, Flora, Coppo, Paul, Scully, Marie, Kremer Hovinga, Johanna A., Metjian, Ara, de la Rubia, Javier, Pavenski, Katerina, Minkue Mi Edou, Jessica, De Winter, Hilde, Callewaert, Filip
Publicado 2019

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

por Scully, Marie, de la Rubia, Javier, Pavenski, Katerina, Metjian, Ara, Knöbl, Paul, Peyvandi, Flora, Cataland, Spero, Coppo, Paul, Kremer Hovinga, Johanna A., Minkue Mi Edou, Jessica, De Passos Sousa, Rui, Callewaert, Filip, Gunawardena, Sriya, Lin, Julie
Publicado 2022